Immunohistochemical expression of programmed death ligand-1 (PDL-1) in colorectal carcinoma and its correlation with stromal tumor infitrating lymphocytes

Abstract

Objectives: Detection of Immunohistochemical (IHC) expression of PDL-1 by tumor cells and stromal tumor infitrating lymphocytes (TILs) in colorectal carcinoma, to investigate the possibility of using it as a targeted therapy, as well as, correlation of this expression with the clinico-pathologic parameters of the tumors. Materials and Methods: Colorectal tissue sections were collected from 60 colectomy specimens were taken from Kasr El Ainy Hospital, Faculty of Medicine, Cairo University. Exclusion criteria included cases with missing data and cases who received chemotherapy or radiotherapy. IHC expression ofPDL-1 was investigated in tumor cells (T) and stromal TILs separately. PDL-1 positivity was defied as PDL-1 expression on = 5% of membranous positive cell staining of any intensity. Results: PDL-1 (T) expression was detected in 25% of cases and showed statistically signifiant correlation with higher tumor grade and right sided colon tumors (P value < 0.05). PD-L1 stromal TILs expression was detected in 38.3 % of cases. Insignifiant statistical relation between Stromal TILs PDL-1 expression and the tumor extent (T) was detected (P value = 0.07), however, the expression of PDL-1 in lymphocytes was inversely proportional to the tumor extent (invasion). There were linear relation between PDL-1 expression stromal (TILs) (33.3%) and PDL-1 expression in tumor cells (28.2%) and positive lympho-vascular invasion but it was statistically insignifiant (P value = 0.4 and 0.2 respectively). Despite there were no statistical relation between either PDL-1 (T) and PDL-stromal TILS and Perineural invasion (P value =1 and 0.5) but inverse relation was noticed with more PDL-1 expression in tumor cells (24.5%) and TILS (40.8%) with negative Perineural invasion. Conclusion: Our results supported PDL-1 expression in CRC by both TC and TILs, with higher expression in subset of tumors that are high grade highlighting them as candidates for anti- PD-1/PDL-1 therapy.